At Extreme Investor Network, we bring you the latest updates on global events that may impact the economy and financial markets. Today, we want to shed light on the rising concern over mpox, the newly branded version of monkeypox, spreading across Asia.
The World Health Organization declared mpox an epidemic in mid-August, following an initial outbreak in African nations. While the WHO emphasizes that mpox is not the new COVID, the demand for vaccinations is on the rise.
In the Philippines, there has been a reported 68% rise in cases, prompting countries like Japan to step up and provide support. Japan has pledged to donate three million doses of the mpox vaccine, making it the largest donation to date. WHO chief Tedros Adhanom Ghebreyesus emphasized the importance of vaccines, therapeutics, and diagnostics in bringing mpox outbreaks under control.
Several countries are actively involved in creating and providing the latest vaccination options. Japan will be providing a version developed by KM Biologics Co, while the MVA-BN vaccine by Bavarian Nordic A/S, produced in Denmark, has also been approved by the WHO. In the UK, 150,000 doses of the Bavarian Nordic vaccination have been purchased. The US FDA has approved an mpox vaccine named JYNNEOS for emergency use, although the CDC is currently only recommending it for those who work with orthopoxviruses.
Despite the rising concerns, governments in developed nations are assuring their citizens that the risk of contracting mpox remains low. However, vaccination is still being encouraged for those most likely to be exposed.
Our team at Extreme Investor Network recognizes the importance of staying informed about global health crises like mpox. While our disease cycle forecasts an uptick in 2026, it is unlikely that mpox will be the next pandemic. Stay tuned for more updates on this evolving situation on our website.